

Volume 2, Issue 5, June 2022

A Review on Role of Nutraceutical in Alzhemer's Disease

Miss. Jagruti V. Kumbhar¹, Miss. Payal S. Rakshe², Miss. Kajal S. Gunjal³ Miss. Pratiksha N. Uchale⁴, Prof. Sachin V. Datkhile⁵ Students, B Pharmacy, Samarth Institute of Pharmacy, Pune, India^{1,2,3,4}

HoD, Samarth Institute of Pharmacy, Pune, India⁵

Abstract: Nutraceuticals are the products derive from food sources with extra health benefits. They can prevent malignant processes. The term 'nutraceuticals' combines two words 'nutrients (a nourishing food component) and 'pharmaceuticals' (a medical drug) The philosophy behind nutraceuticals is according to Hippocrates "Let food be your medicine". Categories of nutraceuticals are dietary supplements, functional food, medicinal food, pharmaceuticals. Advance age is often characterized by a declined in large spectrum of cognitive abilities including reasoning, memory, perceptual speed and language. Alzheimer's disease (AD) is the most common and feared from dementia representing circa 70% of all dementia cases and displaying a dramatic epidemics due to the enormous growth of the aged population worldwide. It is still unclear which factors lead to molecular cascade of neurode generation in AD, but along with genetic environmental factors vascular pathology and risk factor have been recently shown to play crucial role in AD pathogenesis .AD impacts dramatically on everyday life of older adults, being one of the main cause of disability in old age. There is clear evidence that a diet rich in specific nutritional food group (fruit, fish, vegetables) can reduce the incidence and prevalence of some of the main clinical outcomes, such as neurodegenerative disorders, cardiovascular diseases, diabetes, cancer. This specific nutritional food group are rich in micronutrients and vitamins are beneficial for health. The Mediterranean diet is characterized by a high consumption of plant food, fish olive oil as primary source of monounsaturated fat and moderate intake of wine. In this article, we focus our attention on group of substance proposed to prevent or treat Alzheimer's disease.

Keywords: Dementia, antioxidant vitamin, Cognitive impairment, Alzheimer's disease, prebiotics, probiotics, dietary fibres, human diet.

I. INTRODUCTION

Nutraceuticals are items that are both nutritional and medicinal in nature. A nutraceutical product is a chemical that has physiological benefits or provides protection against chronic disease. Nutraceuticals can be used to improve health, reduce the ageing process, prevent chronic diseases, lengthen life, and keep the body's structure and function in good shape. Nutraceuticals have gotten a lot of press recently because of their potential nutritional, safety, and therapeutic benefits. Recent study has shown that these substances have the potential to cause a wide range of issues. The current study worked hard to provide new nutraceutical concepts in Alzheimer's disease.

Alzheimer's disease (AD) is the most common type of dementia and is a chronic neurological illness that often begins slowly and progresses over time. It is the cause of 60–70% of dementia cases in the elderly population if acetylcholine levels are low.

It has been reported. The accumulation of beta amyloid protein in the brain causes Alzheimer's disease.pieces, generating hard plaques that obstruct acetylcholine's ability to affect synaptic transmission.spread of infectious agents and the initiation of inflammatory processes, as well as a change in the chemical composition of In Alzheimer's disease, a particular protein called tau causes neuron death.Tubules are formed when microtubules join with other tubules to form neurofibrillary tangles.Cell death occurs as a result of disintegration and blockage of neurotransmitters. (Marianna and colleagues, 2010). Nutraceuticals are pharmaceutical-quality supplements.



Volume 2, Issue 5, June 2022

IJARSCT



II. STAGES OF ALZHEIMER'S DISEASE

Fig 1 – Stages of Alzheimer's Disease(AD)

Stage 1

Alzheimer's disease usually starts silently, with abnormalities in the brain appearing years before anyone notices anything is amiss. You won't be able to identify any indicators if your loved one is in this stage. A PET scan, a sort of imaging test that demonstrates how the brain works, is the only way to detect if they have Alzheimer's.

Stage 2

You may not notice anything out of the ordinary in your loved one's behaviour, but they may notice minor changes that even a doctor might miss. Things like losing words or misplacing stuff are examples of this.

Stage 3

You may observe changes in your loved one's thinking and reasoning at this point, such as: Forgets what they've just read, asks the same question over and over, and has increasing difficulty planning or organising. When meeting new people, I have trouble remembering names.

Stage 4

During this time, the thinking and reasoning flaws you identified in stage 3 become more apparent, and new issues emerge.

Stage 5

It's possible that your loved one will lose track of where they are and what time it is. They may forget their home location,Copyright to IJARSCTDOI: 10.48175/IJARSCT-4780100www.ijarsct.co.in100



Volume 2, Issue 5, June 2022

phone number, or the school they attended. They can be unsure of what to wear for the day or season.

Stage 6

As Alzheimer's disease progresses, your loved one may recognise faces but forget names. They may even mistake one person for another, such as mistaking their wife for their mother. Delusions may develop, such as the belief that they must go to work even though they do not have one.

Stage 7

During this time, a person with Alzheimer's loses several basic abilities, such as eating, walking, and sitting up.

III. METHODOLOGY

Mechanism of Alzheimer's disease -



Fig 2 - Enzymes act on the APP (amyloid precursor protein) and cut it into fragments. The beta-amyloid fragment is crucial in the formation of senile plaques in AD.

It's unclear how disruptions in beta-amyloid peptide production and aggregation cause the pathophysiology of Alzheimer's disease. The aggregation of beta-amyloid peptides is thought to be the central event that causes neuron degeneration, according to the amyloid hypothesis. Programmed cell death is induced by the accumulation of aggregated amyloid fibrils, which are thought to be the toxic form of the protein responsible for disrupting the cell's calcium ion balance (apoptosis). A is also known to accumulate specifically in the mitochondria of Alzheimer's-affected brain cells, inhibiting some enzyme processes and glucose utilisation by neurons.

Healthy Tar Protein Sarro Arror Microtubules Thermory Tar Protein Sarro Arror Microtubules Thermory Tar Protein Sarror Thermory Thermo

Fig 3 - Progression of Alzheimer's disease

Progression of Alzheimer's disease



International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)

Volume 2, Issue 5, June 2022





Fig 4 How AD Happens?

IV. SYMPTOMS



Fig 5 – Symptoms of AD

Copyright to IJARSCT www.ijarsct.co.in



Volume 2, Issue 5, June 2022

CAUSES

The exact cause of AD aren't fully understood but at its core are problems with brain protein that fail to function normally, disrupts the work of brain cell (neuron).



Fig 6 – Causes of AD

RISK FACTORS



Copyright to IJARSCT www.ijarsct.co.in Fig 7 – Risk Factors of AD DOI: 10.48175/IJARSCT-4780



International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)

Volume 2, Issue 5, June 2022

V. DIAGNOSIS

A diagnosis of Alzheimer's disease is also based on memory and thinking abilities tests administered by your doctor. The full diagnostic toolkit is designed to detect dementia and determine whether it is caused by Alzheimer's disease or another condition with a high degree of accuracy. When microscopic examination of the brain reveals the telltale plaques and tangles, Alzheimer's disease can be diagnosed with absolute confidence after death.

Tests

A diagnostic work-up would likely include the following tests -

Diagnostic tests Psychiatric assessments.

- Mental status examination and neuro psychological assessment.
- Laboratory tests.
- Brain imaging .
 - * CT scan
 - * MRI
 - * PET
 - * SPECT
- CSF Examination
- Electro-encephalogram (EEG)
- Electromyogram

Fig 8 – Diagnostic Tests for AD

Treatment

A number of medicines may be prescribed for Alzheimer's disease to help temporarily improve some symptoms. The main medicines are:

- Acetylcholinesterase inhibitors These medicines increase levels of acetylcholine, a substance in the brain that helps nerve cells communicate with each other. Donepezil, galantamine and rivastigmine can be prescribed for people with early- to mid-stage Alzheimer's disease.
- **Memantine (Nameda)** This medicine is not an AChE inhibitor. It works by blocking the effects of an excessive amount of a chemical in the brain called glutamate. Memantine is used for moderate or severe Alzheimer's disease. It's suitable for those who cannot take or are unable to tolerate AChE.

Molecular mechanism of donepezil:

b.

a.	Formula -	$C_{24}H_{29}NO_3$

Molar mass - $379.50 \text{ g}\cdot\text{mol}^{-1}$



International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)

Volume 2, Issue 5, June 2022

Molecular structure of Donepezil -



Fig 9 – Structure of Donepezil



Fig 10 – Mechanism of Donepezil

Donepezil is an oral medication used to treat Alzheimer's disease. It belongs to a class of drugs called cholinesterase inhibitors that also includes tacrine (Cognex). Scientists believe that Alzheimer's disease may result from a deficiency in chemicals (neurotransmitters) used by nerves in the brain to communicate with one another. Donepezil inhibits acetylcholinesterase, an enzyme responsible for the destruction of one neurotransmitter, acetylcholine. This leads to increased concentrations of acetylcholine in the brain, and the increased concentrations are believed to be responsible for the improvement seen during treatment with donepezil. Donepezil improves the symptoms but does not slow the progression of Alzheimer's disease. Donepezil was approved by the FDA in 1996.



Volume 2, Issue 5, June 2022

IJARSCT



Fig 11 – Natural Remedies for Treatment of AD





International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)

Volume 2, Issue 5, June 2022

VI. PREVENTION



Fig 12 – Prevention of AD

VII. CONCLUSION

- When placed in the context of a healthy lifestyle behaviour, age related changes in nutrition may play an important role in brain functioning as well as in major organ functioning of old people.
- No cure for Alzheimer's disease: medications can help slow the progress of cognitive decline.
- Women are more affected than men at a ratio of almost 2:1 due to in part to the lager population of women who are over 70.



Fig 13 – Risk of AD by age & sex

Copyright to IJARSCT www.ijarsct.co.in



International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)

Volume 2, Issue 5, June 2022

- Benefits for the treatment of symptoms in mild to severe AD using AChEls and Memantine is seen.
- As the cell die, parts of the brain shrink and stop working. There are three telltale signs of AD in the brain:
- Clumps of material in the spaces between brain cells called amyloid plaques.
- Tangles of protein molecules inside brain cell.
- Loss of connection between brain cells.

ACKNOWLEDGMENT

We excess my thanks and gratitude to Trustee of Samarth Rural Educational Institute's and Samarth Institute of Pharmacy, Belhe with their valuable guidance and support.

CONFLICT OF INTEREST

The author declared no conflict of interest.

REFERANCES

- [1]. Cognition Dementia Assessment Measures. (2015). Retrieved from http://www.dementiaassessment.com.au/cognitive/
- [2]. Jun, I.S.Y (2008). What is Alzheimer's Disease? [Video file]. Retrieved from: http://ed.ted.com/lessons/whatis-alzheimer-s-disease-ivan-seah-yu-jun
- [3]. National Institute on Aging. (2015). Alzheimer's Disease, Unraveling the mystery. (NIH Publication No. 08-3782). Retrieved from: https://www.nia.nih.gov/alzheimers/publication/alzheimers-disease-unravelingmystery/preface.
- [4]. PJ Josmi, PD Divya and JM Rosemol A Review On Role of Nutraceuticals in Alzheimer's disease
- [5]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4336979/#:~:text=Nutraceutic%20is%20a%20term%20derive d,used%20as%20medicine.%5B1%5D
- [6]. Cristina Polidori M, Joachim Schlz R. Nutritional contributions to dementia prevention: main issues on antioxidant and micronutrients. Genes Nutr. 2014;9(382).
- [7]. Engel RR, Stzger W, Gunther W, Kathmann N, Bove D, Gerke S et al. Double-blind cross over study of phosphatidylserine vs. placebo in pateints with early dementia of Alzheimer type. Eur Neuropsychopharmacol. 1992; 2:149-155.
- [8]. 8. Falinska AM, Colmbo CB, Irina AG, Mark G, John LH. The role of omega 3- fatty acid in brain function and ameliorating Alzheimer's disease: opportunities for biotechnology in the development of nutraceuticals. Biocatalysis and Agricultural Biotechnology. 2011;1:159-166.
- [9]. Wang C, Holtzman DM. Bidirectional relationship between sleep and Alzheimer's disease: role of amyloid, tau, and other factors. Neuropsychopharmacology 45: 104–120, 2019.
- [10]. Laudon M, Wade AG, Farmer M, Harari G, Fund N, Nir T, Frydman-Marom A, Zisapel N. Add-on prolongedrelease melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: a 6-month, randomized, placebo-controlled, multicenter trial. Clinical Interventions in Aging (2014). doi: 10.2147/cia.s65625.
- [11]. Stark KD, Elswyk MEV, Higgins MR, Weatherford CA, Salem N. Global survey of the omega-3 fatty acids, docosahexaenoic acid and eicosapentaenoic acid in the blood stream of healthy adults. Progress in Lipid Research 63: 132–152, 2016.
- [12]. Quinn JF, Raman R, Thomas RG, Yurko-Mauro K, Nelson EB, Dyck CV, Galvin JE, Emond J, Jack CR, Weiner M, Shinto L, Aisen PS. Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease. Jama 304: 1903, 2010.
- [13]. Kleiner AC, Cladis DP, Santerre CR. A comparison of actual versus stated label amounts of EPA and DHA in commercial omega-3 dietary supplements in the United States. Journal of the Science of Food and Agriculture 95: 1260–1267, 2014.
- [14]. Bronzuoli MR, Facchinetti R, Steardo L, Romano A, Stecca C, Passarella S, Steardo L, Cassano T, Scuderi C. Palmitoylethanolamide Dampens Reactive Astrogliosis and Improves Neuronal Trophic Support in a Triple



Volume 2, Issue 5, June 2022

Transgenic Model of Alzheimer's Disease: In Vitro and In Vivo Evidence. Oxidative Medicine and Cellular Longevity 2018: 1–14, 2018.

- [15]. Beggiato S, Tomasini MC, Ferraro L. Palmitoylethanolamide (PEA) as a Potential Therapeutic Agent in Alzheimer's Disease. Frontiers in Pharmacology 10, 2019.
- [16]. Remington R, Bechtel C, Larsen D, Samar A, Doshanjh L, Fishman P, Luo Y, Smyers K, Page R, Morrell C, Shea TB. A Phase II Randomized Clinical Trial of a Nutritional Formulation for Cognition and Mood in Alzheimer's Disease. Journal of Alzheimer's Disease 45: 395–405, 2015.
- [17]. https://www.webmd.com/alzheimers/guide/alzheimers-disease-stages.